Suggested criteria for using AI/ML algorithms in GxP

08 March 2021

The Danish Medicines Agency (DKMA) is currently working internally, in a European and international context to define criteria for the application of artificial intelligence (AI) and machine learning (ML) across the various GxP-regulated areas. There is nothing in the current legislation that directly addresses the use of AI/ML algorithms and DKMA has therefore written a proposal for criteria and questions that can be expected to be asked for such algorithms.

The proposal applies to static AI/ML algorithms that implement critical GxP-related functions and are trained using supervised learning. The proposal is not intended as a complete set of criteria, more as a, hopefully, mature draft. Comments are very welcome and should be sent by e-mail to Medicines Inspector, GxP IT, Ib Alstrup, no later than 30 April 2021.


Questions to critical GxP AI-ML applications v. 0.9.4 (pdf)

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.